<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33196168</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8937</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>ACS chemical biology</Title><ISOAbbreviation>ACS Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Structural Features of Small Molecules Targeting the RNA Repeat Expansion That Causes Genetically Defined ALS/FTD.</ArticleTitle><Pagination><StartPage>3112</StartPage><EndPage>3123</EndPage><MedlinePgn>3112-3123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschembio.0c00049</ELocationID><Abstract><AbstractText>Genetically defined amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), collectively named c9ALS/FTD, are triggered by hexanucleotide GGGGCC repeat expansions [r(G<sub>4</sub>C<sub>2</sub>)<sup>exp</sup>] within the <i>C9orf72</i> gene. In these diseases, neuronal loss occurs through an interplay of deleterious phenotypes, including r(G<sub>4</sub>C<sub>2</sub>)<sup>exp</sup> RNA gain-of-function mechanisms. Herein, we identified a benzimidazole derivative, CB096, that specifically binds to a repeating 1 &#xd7; 1 GG internal loop structure, 5'C<u>G</u>G/3'G<u>G</u>C, that is formed when r(G<sub>4</sub>C<sub>2</sub>)<sup>exp</sup> folds. Structure-activity relationship (SAR) studies and molecular dynamics (MD) simulations were used to define the molecular interactions formed between CB096 and r(G<sub>4</sub>C<sub>2</sub>)<sup>exp</sup> that results in the rescue of disease-associated pathways. Overall, this study reveals a unique structural feature within r(G<sub>4</sub>C<sub>2</sub>)<sup>exp</sup> that can be exploited for the development of lead medicines and chemical probes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ursu</LastName><ForeName>Andrei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kye Won</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-7907-9732</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baisden</LastName><ForeName>Jared T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Jie</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, Florida 32224, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, Florida 32224, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, Florida 32224, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildirim</LastName><ForeName>Ilyas</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8357-1922</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Disney</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-8486-1796</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS116846</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 NS096898</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021550</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Biol</MedlineTA><NlmUniqueID>101282906</NlmUniqueID><ISSNLinking>1554-8929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054856" MajorTopicYN="N">G-Quadruplexes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare the following competing financial interest(s): M.D.D. is a founder of Expansion Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>16</Day><Hour>14</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33196168</ArticleId><ArticleId IdType="mid">NIHMS1654448</ArticleId><ArticleId IdType="pmc">PMC7788565</ArticleId><ArticleId IdType="doi">10.1021/acschembio.0c00049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balendra R and Isaacs AM (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 14, 544&#x2013;558, DOI: 10.1038/s41582-018-0047-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, and Hermine O (2017) ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?. Front. Aging Neurosci. 9, 68, DOI: 10.3389/fnagi.2017.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, and van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 3, 17071, DOI: 10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B and Robberecht W (2014) The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 10, 661&#x2013;670, DOI: 10.1038/nrneurol.2014.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr., and Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206, DOI: 10.1038/nature20413</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G-YR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, and Rademakers R (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256, DOI: 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Nana AL, Yokoyama JS, and Seeley WW (2019) C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol. 137, 1&#x2013;26, DOI: 10.1007/s00401-018-1921-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1921-0</ArticleId><ArticleId IdType="pmc">PMC6546170</ArticleId><ArticleId IdType="pubmed">30368547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S and Isaacs AM (2014) C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function?. Curr. Opin. Neurol. 27, 515&#x2013;523, DOI: 10.1097/WCO.0000000000000130</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000130</ArticleId><ArticleId IdType="pmc">PMC4165481</ArticleId><ArticleId IdType="pubmed">25188012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Westergard T, Pasinelli P, and Trotti D (2017) Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene. Neurosci. Lett. 636, 16&#x2013;26, DOI: 10.1016/j.neulet.2016.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.09.007</ArticleId><ArticleId IdType="pmc">PMC5148671</ArticleId><ArticleId IdType="pubmed">27619540</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, and Manley JL (2016) The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife 5, e17820 DOI: 10.7554/eLife.17820</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17820</ArticleId><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker HV, Niblock M, Lee Y-B, Shaw CE, and Gallo J-M (2017) RNA misprocessing in C9orf72-linked neurodegeneration. Front. Cell. Neurosci 11, 195&#x2013;195, DOI: 10.3389/fncel.2017.00195</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00195</ArticleId><ArticleId IdType="pmc">PMC5504096</ArticleId><ArticleId IdType="pubmed">28744202</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Linsalata AE, and Todd PK (2016) RAN translation&#x2014;What makes it run?. Brain Res. 1647, 30&#x2013;42, DOI: 10.1016/j.brainres.2016.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC5003667</ArticleId><ArticleId IdType="pubmed">27060770</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD and Taylor JP (2017) The role of dipeptide repeats in C9ORF72-related ALS-FTD. Front. Mol. Neurosci. 10, 35, DOI: 10.3389/fnmol.2017.00035</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5303742</ArticleId><ArticleId IdType="pubmed">28243191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, Pendergast MK, Goldkind SF, Lee EA, Kuniholm A, Soucy A, Vaze J, Belur NR, Fredriksen K, Stojkovska I, Tsytsykova A, Armant M, DiDonato RL, Choi J, Cornelissen L, Pereira LM, Augustine EF, Genetti CA, Dies K, Barton B, Williams L, Goodlett BD, Riley BL, Pasternak A, Berry ER, Pflock KA, Chu S, Reed C, Tyndall K, Agrawal PB, Beggs AH, Grant PE, Urion DK, Snyder RO, Waisbren SE, Poduri A, Park PJ, Patterson A, Biffi A, Mazzulli JR, Bodamer O, Berde CB, and Yu TW (2019) Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644&#x2013;1652, DOI: 10.1056/NEJMoa1813279</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1813279</ArticleId><ArticleId IdType="pmc">PMC6961983</ArticleId><ArticleId IdType="pubmed">31597037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mis MSC, Brajkovic S, Tafuri F, Bresolin N, Comi GP, and Corti S (2017) Development of therapeutics for C9ORF72 ALS/FTD-related disorders. Mol. Neurobiol. 54, 4466&#x2013;4476, DOI: 10.1007/s12035-016-9993-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9993-0</ArticleId><ArticleId IdType="pubmed">27349438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W and Rogge M (2019) Targeting RNA: a transformative therapeutic strategy. Clin. Transl. Sci. 12, 98&#x2013;112, DOI: 10.1111/cts.12624</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12624</ArticleId><ArticleId IdType="pmc">PMC6440575</ArticleId><ArticleId IdType="pubmed">30706991</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorkova O and Wahlestedt C (2017) Oligonucleotide therapies for disorders of the nervous system. Nat. Biotechnol. 35, 249&#x2013;263, DOI: 10.1038/nbt.3784</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3784</ArticleId><ArticleId IdType="pmc">PMC6043900</ArticleId><ArticleId IdType="pubmed">28244991</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor CJ, Laraia L, and Spring DR (2011) Chemical genetics. Chem. Soc. Rev. 40, 4332&#x2013;4345, DOI: 10.1039/c1cs15053g</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c1cs15053g</ArticleId><ArticleId IdType="pubmed">21562678</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert US, Field CM, and Mitchison TJ (2006) Small molecules in an RNAi world. Mol. BioSyst. 2, 93&#x2013;96, DOI: 10.1039/B515335B</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/B515335B</ArticleId><ArticleId IdType="pubmed">16880926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B, Reddy K, Macgregor RB, and Pearson CE (2014) TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J. Biol. Chem. 289, 4653&#x2013;4659, DOI: 10.1074/jbc.C113.502336</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C113.502336</ArticleId><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z-F, Ursu A, Childs-Disney JL, Guertler R, Yang W-Y, Bernat V, Rzuczek SG, Fuerst R, Zhang Y-J, Gendron TF, Yildirim I, Dwyer BG, Rice JE, Petrucelli L, and Disney MD (2019) The hairpin form of r(G4C2)exp in c9ALS/FTD is repeat-associated non-ATG translated and a target for bioactive small molecules. Cell Chem. Biol. 26, 179&#x2013;190, DOI: 10.1016/j.chembiol.2018.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2018.10.018</ArticleId><ArticleId IdType="pmc">PMC6386614</ArticleId><ArticleId IdType="pubmed">30503283</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang W-Y, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh S-Y, Todd PK, Berry JD, Cudkowicz ME, Boeve BF, Dickson D, Floeter MK, Traynor BJ, Morelli C, Ratti A, Silani V, Rademakers R, Brown RH, Rothstein JD, Boylan KB, Petrucelli L, and Disney MD (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83, 1043&#x2013;1050, DOI: 10.1016/j.neuron.2014.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.07.041</ArticleId><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, Balendra R, Moens TG, Preza E, Wilson KM, Heslegrave A, Woodling NS, Niccoli T, Gilbert-Jaramillo J, Abdelkarim S, Clayton EL, Clarke M, Konrad MT, Nicoll AJ, Mitchell JS, Calvo A, Chio A, Houlden H, Polke JM, Ismail MA, Stephens CE, Vo T, Farahat AA, Wilson WD, Boykin DW, Zetterberg H, Partridge L, Wray S, Parkinson G, Neidle S, Patani R, Fratta P, and Isaacs AM (2018) G-quadruplex-binding small molecules ameliorate c9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol. Med. 10, 22&#x2013;31, DOI: 10.15252/emmm.201707850</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707850</ArticleId><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Goodrich KJ, Conlon EG, Gao J, Erbse AH, Manley JL, and Cech TR (2019) C9orf72 and triplet repeat disorder RNAs: G-quadruplex formation, binding to PRC2 and implications for disease mechanisms. RNA 25, 935&#x2013;947, DOI: 10.1261/rna.071191.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.071191.119</ArticleId><ArticleId IdType="pmc">PMC6633194</ArticleId><ArticleId IdType="pubmed">31048495</ArticleId></ArticleIdList></Reference><Reference><Citation>Asare-Okai PN and Chow CS (2011) A modified fluorescent intercalator displacement assay for RNA ligand discovery. Anal. Biochem. 408, 269&#x2013;276, DOI: 10.1016/j.ab.2010.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2010.09.020</ArticleId><ArticleId IdType="pmc">PMC2980581</ArticleId><ArticleId IdType="pubmed">20863807</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran T and Disney MD (2012) Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations. Nat. Commun. 3, 1125, DOI: 10.1038/ncomms2119</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2119</ArticleId><ArticleId IdType="pmc">PMC3533436</ArticleId><ArticleId IdType="pubmed">23047683</ArticleId></ArticleIdList></Reference><Reference><Citation>Haniff HS, Graves A, and Disney MD (2018) Selective small molecule recognition of RNA base pairs. ACS Comb. Sci. 20, 482&#x2013;491, DOI: 10.1021/acscombsci.8b00049</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscombsci.8b00049</ArticleId><ArticleId IdType="pmc">PMC6325646</ArticleId><ArticleId IdType="pubmed">29966095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J-H, Chung TDY, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screening 4, 67&#x2013;73, DOI: 10.1177/108705719900400206</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/108705719900400206</ArticleId><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerabek-Willemsen M, Andr&#xe9; T, Wanner R, Roth HM, Duhr S, Baaske P, and Breitsprecher D (2014) Microscale thermophoresis: interaction analysis and beyond. J. Mol. Struct. 1077, 101&#x2013;113, DOI: 10.1016/j.molstruc.2014.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molstruc.2014.03.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuermann TH, Padrick SB, Gardner KH, and Brautigam CA (2016) On the acquisition and analysis of microscale thermophoresis data. Anal. Biochem. 496, 79&#x2013;93, DOI: 10.1016/j.ab.2015.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2015.12.013</ArticleId><ArticleId IdType="pmc">PMC4873313</ArticleId><ArticleId IdType="pubmed">26739938</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon MH, Hilimire TA, Sanders AM, and Schneekloth JS (2018) Measuring RNA-ligand interactions with microscale thermophoresis. Biochemistry 57, 4638&#x2013;4643, DOI: 10.1021/acs.biochem.7b01141</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.7b01141</ArticleId><ArticleId IdType="pmc">PMC6341465</ArticleId><ArticleId IdType="pubmed">29327580</ArticleId></ArticleIdList></Reference><Reference><Citation>Velagapudi SP, Seedhouse SJ, French J, and Disney MD (2011) Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. J. Am. Chem. Soc. 133, 10111&#x2013;10118, DOI: 10.1021/ja200212b</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja200212b</ArticleId><ArticleId IdType="pmc">PMC3126894</ArticleId><ArticleId IdType="pubmed">21604752</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, Thornton CA, and Disney MD (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J. Am. Chem. Soc. 131, 9767&#x2013;9779, DOI: 10.1021/ja9020149</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9020149</ArticleId><ArticleId IdType="pmc">PMC2731475</ArticleId><ArticleId IdType="pubmed">19552411</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaLucia J Jr. and Turner DH (1993) Structure of (rGGCGAGCC)2 in solution from NMR and restrained molecular dynamics. Biochemistry 32, 12612&#x2013;12623, DOI: 10.1021/bi00210a009</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00210a009</ArticleId><ArticleId IdType="pubmed">8251479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M and Turner DH (1996) Solution structure of (rGCGGACGC)2 by two-dimensional NMR and the iterative relaxation matrix approach. Biochemistry 35, 9677&#x2013;9689, DOI: 10.1021/bi960133q</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi960133q</ArticleId><ArticleId IdType="pubmed">8703939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews DH (2014) RNA secondary structure analysis using RNAstructure. Curr. Protoc. Bioinformatics 46, 1&#x2013;25, DOI: 10.1002/0471250953.bi1206s46</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471250953.bi1206s46</ArticleId><ArticleId IdType="pubmed">24939127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig M, Scott LG, Sperling E, Bermel W, and Williamson JR (2007) Synthesis of 5-fluoropyrimidine nucleotides as sensitive NMR probes of RNA structure. J. Am. Chem. Soc. 129, 14911&#x2013;14921, DOI: 10.1021/ja073825i</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja073825i</ArticleId><ArticleId IdType="pubmed">17990877</ArticleId></ArticleIdList></Reference><Reference><Citation>Puffer B, Kreutz C, Rieder U, Ebert M-O, Konrat R, and Micura R (2009) 5-Fluoro pyrimidines: labels to probe DNA and RNA secondary structures by 1D 19F NMR spectroscopy. Nucleic Acids Res. 37, 7728&#x2013;7740, DOI: 10.1093/nar/gkp862</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp862</ArticleId><ArticleId IdType="pmc">PMC2794194</ArticleId><ArticleId IdType="pubmed">19843610</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber D, Moroder H, and Micura R (2008) 19F NMR spectroscopy for the analysis of RNA secondary structure populations. J. Am. Chem. Soc. 130, 17230&#x2013;17231, DOI: 10.1021/ja806716s</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja806716s</ArticleId><ArticleId IdType="pubmed">19053191</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott LG, and Hennig M (2016) 19F-site-specific-labeled nucleotides for nucleic acid structural analysis by NMR, Methods Enzymol. (Kelman Z, Ed.), pp 59&#x2013;87, Academic Press, New York.</Citation><ArticleIdList><ArticleId IdType="pubmed">26791976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Anklin C, and Greenbaum NL (2014) Use of 19F NMR methods to pobe conformational heterogeneity and dynamics of exchange in functional RNA molecules, Methods Enzymol. (Burke-Aguero DH, Ed.), pp 267&#x2013;285, Academic Press, New York.</Citation><ArticleIdList><ArticleId IdType="pubmed">25432753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierzek R, Burkard ME, and Turner DH (1999) Thermodynamics of single mismatches in RNA duplexes. Biochemistry 38, 14214&#x2013;14223, DOI: 10.1021/bi991186l</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi991186l</ArticleId><ArticleId IdType="pubmed">10571995</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkard ME and Turner DH (2000) NMR structures of r(GCAGGCGUGC)2 and determinants of stability for single guanosine-guanosine base pairs. Biochemistry 39, 11748&#x2013;11762, DOI: 10.1021/bi000720i</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi000720i</ArticleId><ArticleId IdType="pubmed">10995243</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;poner J, Bussi G, Krepl M, Ban&#xe1;&#x161; P, Bottaro S, Cunha RA, Gil-Ley A, Pinamonti G, Poblete S, Jure&#x10d;ka P, Walter NG, and Otyepka M (2018) RNA structural dynamics as captured by molecular simulations: a comprehensive overview. Chem. Rev. 118, 4177&#x2013;4338, DOI: 10.1021/acs.chemrev.7b00427</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.7b00427</ArticleId><ArticleId IdType="pmc">PMC5920944</ArticleId><ArticleId IdType="pubmed">29297679</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Oglio E, Caro MB, Gesser JC, Zucco C, and Rezende MC (2002) The influence of substituents on the tautomerism of symmetrically substituted 2,2&#x2032;-bis-benzimidazoles. J. Braz. Chem. Soc. 13, 251&#x2013;259, DOI: 10.1590/S0103-50532002000200018</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0103-50532002000200018</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto CI, Cabildo P, Garcia MA, Claramunt RM, Alkorta I, and Elguero J (2014) An experimental and theoretical NMR study of NH-benzimidazoles in solution and in the solid state: proton transfer and tautomerism. Beilstein J. Org. Chem. 10, 1620&#x2013;1629, DOI: 10.3762/bjoc.10.168</Citation><ArticleIdList><ArticleId IdType="doi">10.3762/bjoc.10.168</ArticleId><ArticleId IdType="pmc">PMC4142846</ArticleId><ArticleId IdType="pubmed">25161719</ArticleId></ArticleIdList></Reference><Reference><Citation>Costales MG, Aikawa H, Li Y, Childs-Disney JL, Abegg D, Hoch DG, Pradeep Velagapudi S, Nakai Y, Khan T, Wang KW, Yildirim I, Adibekian A, Wang ET, and Disney MD (2020) Small molecule targeted recruitment of a nucleaase to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proc. Natl. Acad. Sci. U. S. A. 117, 2406&#x2013;2411, DOI: 10.1073/pnas.1914286117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1914286117</ArticleId><ArticleId IdType="pmc">PMC7007575</ArticleId><ArticleId IdType="pubmed">31964809</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs-Disney JL, Yildirim I, Park H, Lohman JR, Guan L, Tran T, Sarkar P, Schatz GC, and Disney MD (2014) Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity. ACS Chem. Biol. 9, 538&#x2013;550, DOI: 10.1021/cb4007387</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb4007387</ArticleId><ArticleId IdType="pmc">PMC3944380</ArticleId><ArticleId IdType="pubmed">24341895</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs-Disney JL, Stepniak-Konieczna E, Tran T, Yildirim I, Park H, Chen CZ, Hoskins J, Southall N, Marugan JJ, Patnaik S, Zheng W, Austin CP, Schatz GC, Sobczak K, Thornton CA, and Disney MD (2013) Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat. Commun. 4, 2044, DOI: 10.1038/ncomms3044</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3044</ArticleId><ArticleId IdType="pmc">PMC3710115</ArticleId><ArticleId IdType="pubmed">23806903</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BR, McGee TD, Swails JM, Homeyer N, Gohlke H, and Roitberg AE (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314&#x2013;3321, DOI: 10.1021/ct300418h</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct300418h</ArticleId><ArticleId IdType="pubmed">26605738</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauz&#xe1; A, Frontera A, and Mooibroek TJ (2019) &#x3c0;-hole interactions involving nitro aromatic ligands in protein structures. Chem. - Eur. J 25, 13436&#x2013;13443, DOI: 10.1002/chem.201903404</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/chem.201903404</ArticleId><ArticleId IdType="pmc">PMC6856858</ArticleId><ArticleId IdType="pubmed">31453653</ArticleId></ArticleIdList></Reference><Reference><Citation>Franconetti A, Frontera A, and Mooibroek TJ (2019) Intramolecular &#x3c0;-hole interactions with nitro aromatics. CrystEngComm 21, 5410&#x2013;5417, DOI: 10.1039/C9CE01015G</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9CE01015G</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauz&#xe1; A, Mooibroek TJ, and Frontera A (2015) Directionality of &#x3c0;-holes in nitro compounds. Chem. Commun. 51, 1491&#x2013;1493, DOI: 10.1039/C4CC09132A</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4CC09132A</ArticleId><ArticleId IdType="pubmed">25493451</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;uza A, Frontera A, and Mooibroek TJ (2016) &#x3c0;-hole interactions involving nitro compounds: directionality of nitrate esters. Cryst. Growth Des. 16, 5520&#x2013;5524, DOI: 10.1021/acs.cgd.6b00989</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.cgd.6b00989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu Y-F, Katzman RB, Gass J, Murray ME, Shinohara M, Lin W-L, Garrett A, Stankowski JN, Daughrity L, Tong J, Perkerson EA, Yue M, Chew J, Castanedes-Casey M, Kurti A, Wang ZS, Liesinger AM, Baker JD, Jiang J, Lagier-Tourenne C, Edbauer D, Cleveland DW, Rademakers R, Boylan KB, Bu G, Link CD, Dickey CA, Rothstein JD, Dickson DW, Fryer JD, and Petrucelli L (2016) C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 19, 668&#x2013;677, DOI: 10.1038/nn.4272</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4272</ArticleId><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu SL, Huganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, and Rothstein JD (2015) The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61, DOI: 10.1038/nature14973</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, Taylor JP, Gitler AD, Rothstein JD, and Lloyd TE (2018) Stress granule assembly disrupts nucleocytoplasmic transport. Cell 173, 958&#x2013;971, e917 DOI: 10.1016/j.cell.2018.03.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM, Castanedes-Casey M, Kurti A, Stankowski JN, Disney MD, Rothstein JD, Dickson DW, Fryer JD, Zhang YJ, and Petrucelli L (2019) Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol. Neurodegener. 14, 9, DOI: 10.1186/s13024-019-0310-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0310-z</ArticleId><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-H, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin M, Messing J, Molliex A, Maxwell BA, Kim NC, Temirov J, Moore J, Kolaitis R-M, Shaw TI, Bai B, Peng J, Kriwacki RW, and Taylor JP (2016) C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell 167, 774&#x2013;788, e717 DOI: 10.1016/j.cell.2016.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen E, Kedersha N, Song B, Scheuner D, Gilks N, Han A, Chen JJ, Anderson P, and Kaufman RJ (2005) Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. J. Biol. Chem. 280, 16925&#x2013;16933, DOI: 10.1074/jbc.M412882200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M412882200</ArticleId><ArticleId IdType="pubmed">15684421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstam L and Nriagu J (2000) Molecular aspects of arsenic stress. J. Toxicol. Environ. Health, Part B 3, 293&#x2013;322, DOI: 10.1080/109374000436355</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/109374000436355</ArticleId><ArticleId IdType="pubmed">11055208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>